Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Net Cash Flow (2022 - 2025)

Stoke Therapeutics has reported Net Cash Flow over the past 4 years, most recently at $826000.0 for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 103.79% year-over-year to $826000.0; the TTM value through Dec 2025 reached -$43.8 million, up 30.67%, while the annual FY2025 figure was -$43.8 million, 30.67% up from the prior year.
  • Net Cash Flow for Q4 2025 was $826000.0 at Stoke Therapeutics, up from -$18.2 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $146.8 million in Q1 2025 and troughed at -$173.3 million in Q2 2025.
  • A 4-year average of -$3.8 million and a median of -$961500.0 in 2022 define the central range for Net Cash Flow.
  • Biggest five-year swings in Net Cash Flow: crashed 1986.41% in 2024 and later surged 1241.69% in 2025.
  • Year by year, Net Cash Flow stood at $160000.0 in 2022, then surged by 815.62% to $1.5 million in 2023, then crashed by 1588.46% to -$21.8 million in 2024, then skyrocketed by 103.79% to $826000.0 in 2025.
  • Business Quant data shows Net Cash Flow for STOK at $826000.0 in Q4 2025, -$18.2 million in Q3 2025, and -$173.3 million in Q2 2025.